Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Misses Revenue Estimates
Sera Prognostics (SERA) delivered earnings and revenue surprises of +15.79% and -75.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
How this was made

The 30-second read
Why it matters
The earnings miss has led to a negative market reaction, affecting stock price and investor sentiment.
Market read
The news is highly relevant for investors holding or considering investing in SERA, with potential short-term trading opportunities.
What to watch
Potential upcoming catalysts such as new product launches or strategic partnerships that could positively influence stock performance.
Background
Sera Prognostics specializes in prenatal diagnostics and has recently reported Q3 2025 earnings that fell short of expectations.
Ticker impact
Primary focus of the news, given the company's recent earnings report.
Potential short-term decline of 10-15%, with recovery depending on upcoming earnings and market conditions.
The earnings miss and revenue decline are concrete facts, but market reactions can be unpredictable. The negative sentiment is supported by the earnings data, but broader market trends could mitigate or exacerbate the impact.
Market effects
Potential negative impact on biotech and diagnostics sector due to earnings miss.
Limited, primarily affecting stock-specific sentiment.
Negligible, as the news pertains to a single company.
Counterpoint
The earnings miss may be a temporary setback; company fundamentals could improve in the next quarter, providing a buying opportunity at lower prices.
Key entities
- CompanySera Prognostics, Inc.
A biotech company focused on prenatal diagnostics.





